



# Società moderna



- % of people over 65y


# Società moderna



Johanna Quaas, 86 years old




Lignano (ITA) Master Games 2011



Hairi N, [www.intechopen.com](http://www.intechopen.com) 2008

# INTRODUCTION

## BODY COMPOSITION



## MUSCLE:


- the most represented tissue in the body
- 20% is proteins
- the tissue containing most of body proteins
- has multiple functions:
  - Movement-posture
  - Metabolism
  - Endocrine (myokines)

# INTRODUCTION


## SARCOPENIA

“syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength, with a risk of adverse outcomes such as physical disability, poor quality of life and death”

European Working Group on Sarcopenia in Older People (EWGSOP)  
2012




Young woman  
(21y, BMI 24.3 kg/m<sup>2</sup>)




Elderly woman  
(73y, BMI 24.5 kg/m<sup>2</sup>)

# SARCOPENIA




# SARCOPENIA: Anabolic resistance



the inability to increase protein synthesis in response to a meal induced higher amino acid availability.


Biolo G et al. *Clin Nutr* 2014



# Aging is associated with diminished accretion of muscle proteins after the ingestion of a small bolus of essential amino acids<sup>1-3</sup>


Christos S Katsanos, Hisamine Kobayashi, Melinda Sheffield-Moore, Asle Aarland, and Robert R Wolfe

*Am J Clin Nutr* 2005;82:1065-73.



Mean ( $\pm$ SEM) leg phenylalanine net balance 3.5 h after the ingestion of essential amino acids calculated by measuring the area under the phenylalanine net balance response curve (in the calculations, basal net balance was taken as zero) in the elderly ( $n = 11$ ) and the young ( $n = 8$ ). Data were analyzed with a *t* test. \*Significantly different from the young,  $P = 0.010$ .

# SARCOPENIA: effects of immobilization




BED REST



**Short-term bed rest impairs amino acid-induced protein anabolism in humans**

# EFFECTS OF AMINO ACID INFUSION ON SKELETAL MUSCLE PROTEIN BALANCE IN SEVERELY BURNED PATIENTS




\*,  $P < 0.05$  vs. postabsorptive state

#,  $P < 0.05$  vs. healthy volunteers

# INTRODUCTION



## SARCOPENIA: Body weight and composition in aging

**CROSS-SECTIONAL STUDY**  
252 healthy subjects with normal  
body mass index, 35 to 65 years



# INTRODUCTION

## SARCOPENIA: Role of fat mass and inflammation






Zamboni et al., Nutrition, Metabolism & Cardiovascular Diseases 2008

**Inter-relationships between adipose tissue and muscle. A mechanism leading to sarcopenic obesity.**

# INTRODUCTION

## SARCOPENIA



## SARCOPENIC OBESITY

# COMPOSIZIONE CORPOREA

## OBESITÀ SARCOPENICA

Sindrome caratterizzata da progressiva e generalizzata alterazione della composizione corporea, con:


- **eccesso di tessuto adiposo (obesità)**
- **ridotti massa e funzionalità muscolari (sarcopenia)**

**Prevalenza maggiore in anziani e persone affette da malattie croniche**


**Interferisce negativamente con**

- **capacità fisica**
- **metabolismo**
- **funzione cardiovascolare**

**con conseguente peggioramento della qualità della vita, aumento della morbilità e della mortalità.**



# Correlation between waist circumference and age



Correlations were examined in longitudinal data for waist circumference in all subjects (21,358). The line represents a least-squares plot of the data.  $P=4.34 \times 10^{-60}$ ,  $R^2=0.0124$ , waist circumference (cm) =  $76.0696 + 0.0893x$ ;

# Società moderna



Johanna Quaas, 86 years old




Pengzue Su ,87-year old

# SARCOPENIA: Oxidative stress

“An imbalance between oxidants and antioxidants in favor of the oxidants, potentially leading to damage, is termed *oxidative stress*”.


*Sies H. Exp Physiol. 1997*




*Powers SK et al. Antioxid. Redox Signal. 2011 - modified*

# Glutathione synthetic capacity directly modulates oxidative stress

RELATIONSHIP BETWEEN BED REST-INDUCED CHANGES IN GLUTATHIONE SYNTHESIS AND PROTEIN CARBONYLATION



# CHRONIC DISEASES AND MUSCLE WAISTING



# Recommended Dietary Allowance (RDA) for protein

**~0.83 g/kg/d**

European Food Safety Agency, 2012  
Food and Nutrition Board, 2002

## Net balance of body proteins

Difference between *nitrogen intake* and *total nitrogen loss*

Nitrogen Balance  
technique has  
limitations

Systematic errors:

overestimated intake  
underestimated losses

(Millward DJ. J Nutr. 1998)

Conceptual limitation:

metabolic adaptation to nitrogen intakes

(Young VR. J Nutr. 1986)

**RDA**




No differences between gender and age

(Conley TB et al. J Nutr Biochem. 2013)

# PROTEINE


**Macronutrienti** con significato **plastico, funzionale ed energetico**

Le **unità di base** che compongono le molecole sono gli **amminoacidi** caratterizzati da un **gruppo amminico (-NH<sup>+</sup><sub>3</sub>)** da un **gruppo carbossilico (-COOH)** e da un **gruppo -R laterale**, legati a un atomo centrale di carbonio.



Gli amminoacidi vengono classificati in funzione delle proprietà chimiche del gruppo -R come acidi, basici, idrofili (o *polarì*) e idrofobi (o *apolarì*).


# METABOLISMO DELLE PROTEINE



**Il pool di amminoacidi presente nel sangue è la risultante dei diversi fattori dall'introito alimentare al metabolismo proteico**


# SINTESI DELLE PROTEINE

Stimolata soprattutto dagli amminoacidi introdotti con i pasti in particolare amminoacidi ramificati, (soprattutto leucina con attivazione del complesso proteico TORC 1, mammalian target of rapamycin complex) che funge da sensore dell'apporto di nutrienti




**Le sintesi proteiche richiedono quindi disponibilità di substrati amminoacidici**

# METABOLIC INDICES IN SKELETAL MUSCLE BIOPSIES



# VIE PROTEOLITICHE DELLE PROTEINE

## Sistema endosoma/lisososma e Ubiquitina/proteosoma



- ❖ endosome-lysosome pathway degrades extracellular and cell-surface proteins
- ❖ ubiquitin-proteasome pathway degrades proteins from the cytoplasm, nucleus and ER

# TURNOVER PROTEICO


La continua demolizione e sintesi è fondamentale per

- degradare e rimpiazzare proteine danneggiate
- modificare la quantità relativa di differenti proteine in base alle necessità nutrizionali e fisiologiche
- rapido adattamento metabolico

**La regolazione del turnover proteico è influenzata da:**

- **stato nutrizionale** (energetico e proteico)
- **da alcuni ormoni** (insulina, glucocorticoidi, ormoni tiroidei, ormone della crescita, citochine)

# REGOLAZIONE ORMONALE DELLE SINTESI E DEL CATABOLISMO DELLE PROTEINE



# DIGESTIONE E ASSORBIMENTO DELLE PROTEINE



## STOMACO

L'acido idrocloridrico denatura le proteine e attiva il **pepsinogeno in pepsina**, enzima che frammenta le catene polipeptidiche in polipeptidi di più piccole dimensioni

## INTESTINO TENUE

Gli **enzimi pancreatici** secreti nel lume intestinale scindono ulteriormente i legami peptidici dando origine a dipeptidi, tripeptidi e singoli aminoacidi.


Le **tripeptidasi e dipeptidasi** di origine intestinale portano a termine la digestione dei frammenti peptidici a singoli aminoacidi che vengono assorbiti.




Denatured protein



Polypeptide chain



Tripeptides and single amino acids



Single amino acids

# CLASSIFICAZIONE CHIMICA DEGLI AMMINOACIDI

## CATENE LATERALI

**Neutre apolari:** alanina, fenilalanina, glicina, leucina, isoleucina, metionina, prolina triptofano , valina

**Neutre polari:** asparagina, glutammina, serina, treonina cisteina, tirosina

**Carica acida:** aspartico, glutammico

**Carica basica:** arginina , istidina, lisina

# AMINOACIDI ESSENZIALI E NON ESSENZIALI

## ESSENZIALI

- ❖ Sono amminoacidi che l'organismo umano non è in grado di sintetizzare e che perciò devono essere introdotti con la dieta
- ❖ **Sono essenziali:** lisina, leucina, isoleucina, metionina, fenilalanina, treonina, triptofano, valina e istidina.
- ❖ Il fabbisogno dell'istidina si riduce in età adulta, mentre è più elevato nei bambini e nelle donne in gravidanza

# AMINOACIDI ESSENZIALI E NON ESSENZIALI

## NON ESSENZIALI

Sono amminoacidi che l'organismo è in grado di sintetizzare. Vanno comunque integrati con la dieta con un apporto bilanciato in quanto il pool di amminoacidi non è totalmente riutilizzabile (fabbisogno di azoto)

## SEMI-ESSENZIALI


- ❖ Possono derivare da amminoacidi essenziali precursori
- ❖ Tirosina sintetizzata da fenilalanina
- ❖ Cisteina sintetizzata da metionina
- ❖ Tuttavia il loro apporto ha un'azione di risparmio sui precursori

## ❖ CONDIZIONATAMENTE ESSENZIALI


Diventano essenziali in condizioni patologiche

# AMMINOACIDI RAMIFICATI


BCAA, Branched chain amino acids



Valine




Leucine



Isoleucine

- promuovono le sintesi proteiche e
- regolano il metabolismo del glucosio (insulin-like effect)

# METABOLISMO DEGLI AMMINOACIDI




❖ Dopo un pasto proteico e la digestione proteica gli aminoacidi assorbiti raggiungono il fegato attraverso la vena porta


❖ Qui vengono transaminati prima di raggiungere la circolazione sistemica o essere utilizzata come fonte alternativa di energia

❖ I BCAA invece, raggiunto il fegato lo bypassano. Dopo un pasto la concentrazione ematica degli BCAA aumenta in modo significativo e raggiunge altri tessuti (muscoli scheletrici, pancreas, tessuto adiposo, cervello) dove vengono metabolizzati da Branched-chain amino acid transaminase (BCAT).


# AMMINOACIDI AROMATICI




Fenilalanina



Triptofano



Tirosina




Istidina


## ALCUNI DERIVATI

- ❖ Fenilalanina → Tirosina →→ Dopamina → Norepinefrina → Epinefrina
- ❖ Fenilalanina → Tirosina → Tiroxina
- ❖ Triptofano → 5-idrossitriptofano → Serotonina

# AMMINOACIDI SOLFORATI



**Metionina**



**Cisteina**

## **METIONINA**


Sintesi della cisteina e quindi del Glutatione  
Carnitina, Fosfolipidi, donatore di metili

# AMMINOACIDI CHETOGENICI E GLUCOGENICI


in giallo  
a.a.  $\Rightarrow$  glucosio

in celeste  
a.a.  $\Rightarrow$  corpi chetonici

in rosa  
a.a.  $\Rightarrow$  glucosio e corpi chetonici



# DESTINO METABOLICO DEGLI AMMINOACIDI



## **TURNOVER PROTEICO**

Le proteine vanno incontro a continui processi di anabolismo e catabolismo. Inoltre gli amminoacidi entrano nella sintesi di diversi prodotti derivati

**Trasporto di azoto** (glutammina, alanina)

**Regolazione sintesi**

**AA ramificati, leucina**

**Ormoni**

## **NEOGLUCOGENESI**

In condizioni di introito proteico superiore ai fabbisogni gli amminoacidi possono contribuire alla neoglucogenesi

## **PRODUZIONE ENERGIA**

Gli amminoacidi possono essere utilizzati per la produzione di energia, specie in condizioni di carenza di altri substrati energetici

## **SINTESI ACIDI GRASSI**

In condizioni di apporto proteico superiore ai fabbisogni gli amminoacidi possono essere convertiti in acidi grassi, accumulati come trigliceridi nel tessuto adiposo

# DESTINO METABOLICO DI AMMINOACIDI PRECURSORI DI COMPOSTI AZOTATI

## *amminoacidi precursori*

---

glicina (+ succinil CoA)

glutammina, glicina, acido aspartico

lisina, metionina

arginina, glicina, metionina

istidina, triptofano, tirosina, glutammato

*ormoni, neurotrasmettitori, ammine di interesse farmacologico*

tirosina

cisteina (*sali biliari, neuromodulatore*)

glutammina (*amminozuccheri*)

arginina (*vasodilatatore, inibisce aggregazione piastrinica*)

triptofano (*1mg vit equivale a 60 mg a.a.*)

---

glutammico, cisteina, glicina

## *composti derivati*

---

**Eme**

**Nucleotidi**

**Carnitina**

**Creatina**

**Ammine biogene**

**Tiroxina, adrenalina**

**Taurina**

**Glucosammina**

**Ossido nitrico (NO)**

**Niacina**

---

**Glutatione**

# DESTINO METABOLICO DI ALCUNI AMMINOACIDI

- ❖ **Componenti di peptidi** glutatione (GSH)  $\gamma$ Glu-Cys-Gly
- ❖ **Intermedi metabolici** ornitina
- ❖ **Fonte energetica** a.a. glucogenici, a.a. chetogenici
- ❖ **Regolatori del turnover proteico** leucina, glutammina
- ❖ **Trasporto di azoto** glutammina, alanina

# PRINCIPALI FUNZIONI DELLE PROTEINE

- Attività enzimatica
- Recettori - attività di signaling
- Strutturali – es. collagene, cheratina, proteine muscolari
- Attività motoria, equilibrio (proteine muscolari)
- Immunità, tra cui anticorpi
- Ormoni tra cui Insulina, glucagone, leptina, ecc.
- Neuropeptidi
- Trasporto - albumina, tranferrina, emoglobina, lipoproteine , ecc.
- Osmolarità plasmatica, regolazione bilancio idrico
- Funzione energetica
- Riserva azotata. **Di fatto NON ESISTONO PROTEINE DI RISERVA** ed ogni perdita proteica si associa a perdita di funzione (da impercettibile e rilevante)

# PROTEIN INTAKE

*quantity*

*&*

*quality*

*protein quantity*

# Recommended Dietary Allowance (RDA) for protein

~0.83 g/kg/d

European Food Safety Agency, 2012  
Food and Nutrition Board, 2002

RDA → No differences between gender and age  
(Conley TB et al. J Nutr Biochem. 2013)

## Optimal protein intake in the elderly

Robert R. Wolfe<sup>a,\*</sup>, Sharon L. Miller<sup>b</sup>, Kevin B. Miller<sup>c</sup>

“The RDA was based on the results of the available studies that estimated the minimum protein intake necessary to avoid a progressive loss of lean body mass as determined by nitrogen balance and may, therefore, not be adequate in many conditions”

Clinical Nutrition (2008) 27, 675–684

## Optimal protein intake in the elderly

Robert R. Wolfe<sup>a,\*</sup>, Sharon L. Miller<sup>b</sup>, Kevin B. Miller<sup>c</sup>

There is an evidence that **the RDA for elderly** may be **greater than 0.8 g/kg/day** to **improve muscle mass, strength and function** as well as to improve immune status, wound healing, blood pressure and bone health

Clinical Nutrition (2008) 27, 675–684

“Protein intakes above the RDA value have no benefit and may pose long-term health risks.”

Conley TB et al. J Nutr Biochem.

*Higher protein intake has been shown to be useful in subjects with:*

- Ageing
- COPD
- Obesity
- Type 2 diabetes
- Heart disease

(accepted)

(controversial)

(controversial)

(controversial)


(controversial)

**SARCOPENIA**



Layman DK *Nutrition & Metabolism*, 2009

# Protein and energy supplementation in elderly people at risk from malnutrition

Cochrane Database Syst Rev 2009



62 trials  
10,187 participants  
commercial “sip-feeds”  
intervention < 18 months



# Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Jürgen Bauer MD<sup>a,\*</sup>, Gianni Biolo MD, PhD<sup>b</sup>, Tommy Cederholm MD, PhD<sup>c</sup>, Matteo Cesari MD, PhD<sup>d</sup>, Alfonso J. Cruz-Jentoft MD<sup>e</sup>, John E. Morley MB, BCh<sup>f</sup>, Stuart Phillips PhD<sup>g</sup>, Cornel Sieber MD, PhD<sup>h</sup>, Peter Stehle MD, PhD<sup>i</sup>, Daniel Teta MD, PhD<sup>j</sup>, Renuka Visvanathan MBBS, PhD<sup>k</sup>, Elena Volpi MD, PhD<sup>l</sup>, Yves Boirie MD, PhD<sup>m</sup>

<sup>a</sup>Geriatric Centre Oldenburg, Oldenburg, Germany

<sup>b</sup>University of Trieste, Trieste, Italy

<sup>c</sup>Uppsala University, Uppsala, Sweden

<sup>d</sup>Université de Toulouse III Paul Sabatier, INSERM UMR1027, Toulouse, France

<sup>e</sup>Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>f</sup>Saint Louis University School of Medicine, St. Louis, MO

<sup>g</sup>McMaster University, Hamilton, Ontario, Canada

<sup>h</sup>Friedrich-Alexander-University Erlangen-Nürnberg, Nürnberg, Germany

<sup>i</sup>University of Bonn, Bonn, Germany

<sup>j</sup>Centre Hospitalier Universitaire Vaudois, Service de Néphrologie, Lausanne, Switzerland

<sup>k</sup>University of Adelaide, Adelaide, Australia

<sup>l</sup>University of Texas Medical Branch, Galveston, TX

<sup>m</sup>Université d'Auvergne, INRA, CRNH, Centre Hospitalier Universitaire, Clermont-Ferrand, France

## PROT-AGE recommendations for protein levels in geriatric patients with specific acute or chronic diseases

- The amount of additional dietary protein or supplemental protein needed depends on the disease, its severity, the patient's nutritional status prior to disease, as well as the disease impact on the patient's nutritional status.
- Most older adults who have an acute or chronic disease need more dietary protein (ie, 1.2–1.5 g/kg BW/d); people with severe illness or injury or with marked malnutrition may need as much as 2.0 g/kg BW/d.
- Older people with severe kidney disease (ie, estimated glomerular filtration rate [GFR] < 30 mL/min/1.73m<sup>2</sup>) who are not on dialysis are an exception to the high-protein rule; these individuals need to limit protein intake.

**CHRONIC DISEASES**

424 subjects with Cardiovascular Disease were enrolled at the “Cardiovascular Centre” of the Ospedale Maggiore (Trieste, Italy).



	Male (n=237)	Female (n=187)	Total (n=424)
AGE	68 ± 12	69 ± 14	68 ± 13
BMI	26 [24-30]	25 [22-28]	26 [23-29]
Abdominal circumference	98 [92-108]	90 [80-97]	95 [88-103]
CVD	73%	61%	68%
CV Events	30%	18%	25%

## Protein intake according to level of physical activity

	METS = 0 (n=238 - <b>61,6%</b> )	METS > 0 (n=148 - 38,4%)	p-value
GFR	64 ± 24	71 ± 21	0,665
<b>Proteine g/kg/die</b>	<b>0,52 [0,42-0,63]</b>	<b>0,55 [0,43-0,67]</b>	<b>0,035</b>
Eventi CV	25,6%	24,3%	0,774
Patologie CV	71,8%	62,2%	0,047
Rischio CV molto alto	54,6%	56,1%	0,779

- Only the 8% of the population reach the recommended protein intake (1 - 1,2 g/kg/die)
- Higher percentage of inactive subjects (61,6%)
- Lower protein intake in the inactive subjects
- High risk of SARCOPENIA

# Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Jürgen Bauer MD<sup>a,\*</sup>, Gianni Biolo MD, PhD<sup>b</sup>, Tommy Cederholm MD, PhD<sup>c</sup>, Matteo Cesari MD, PhD<sup>d</sup>, Alfonso J. Cruz-Jentoft MD<sup>e</sup>, John E. Morley MB, BCh<sup>f</sup>, Stuart Phillips PhD<sup>g</sup>, Cornel Sieber MD, PhD<sup>h</sup>, Peter Stehle MD, PhD<sup>i</sup>, Daniel Teta MD, PhD<sup>j</sup>, Renuka Visvanathan MBBS, PhD<sup>k</sup>, Elena Volpi MD, PhD<sup>l</sup>, Yves Boirie MD, PhD<sup>m</sup>

<sup>a</sup> Geriatric Centre Oldenburg, Oldenburg, Germany

<sup>b</sup> University of Trieste, Trieste, Italy

<sup>c</sup> Uppsala University, Uppsala, Sweden

<sup>d</sup> Université de Toulouse III Paul Sabatier, INSERM UMR1027, Toulouse, France

<sup>e</sup> Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>f</sup> Saint Louis University School of Medicine, St. Louis, MO

<sup>g</sup> McMaster University, Hamilton, Ontario, Canada

<sup>h</sup> Friedrich-Alexander-University Erlangen-Nürnberg, Nürnberg, Germany

<sup>i</sup> University of Bonn, Bonn, Germany

<sup>j</sup> Centre Hospitalier Universitaire Vaudois, Service de Néphrologie, Lausanne, Switzerland

<sup>k</sup> University of Adelaide, Adelaide, Australia

<sup>l</sup> University of Texas Medical Branch, Galveston, TX

<sup>m</sup> Université d'Auvergne, INRA, CRNH, Centre Hospitalier Universitaire, Clermont-Ferrand, France

## HEALTHY AGEING

### PROT-AGE recommendations for dietary protein intake in *healthy* older adults

- To maintain and regain muscle, older people need more dietary protein than do younger people; older people should consume an average daily intake in the range of 1.0 to 1.2 g/kg BW/d.
- The per-meal anabolic threshold of dietary protein/amino acid intake is higher in older individuals (ie, 25 to 30 g protein per meal, containing about 2.5 to 2.8 g leucine) in comparison with young adults.
- Protein source, timing of intake, and amino acid supplementation may be considered when making recommendations for dietary protein intake by older adults.
- More research studies with better methodologies are desired to fine tune protein needs in older adults.

## Nondialysis CKD

---

PROT-AGE recommendations  
for older people with kidney  
disease

- **Severe CKD, GFR <30\***: Limit protein intake to 0.8 g/kg BW<sup>†</sup>/d
  - **Moderate CKD, 30 <GFR <60**: Protein >0.8 g/kg BW<sup>†</sup>/d is safe, but GFR should be monitored 2x/year
  - **Mild CKD, GFR >60**: Increase protein intake per patient needs
- 

## Hemodialysis

---

>1.2 g/kg BW<sup>†</sup>/d or, if achievable,  
1.5 g/kg BW<sup>†</sup>/d<sup>‡</sup>

## Peritoneal Dialysis

---

>1.2 g/kg BW<sup>†</sup>/d or, if achievable,  
1.5 g/kg BW<sup>†</sup>/d<sup>‡</sup>

JAMDA 14 (2013) 542–559


BW, body weight; CKD, chronic kidney disease; GFR, glomerular filtration rate.

\*GFR is measured in mL/min/1.73 m<sup>2</sup>.


<sup>†</sup>Recommendations are based on ideal body weight. Regular follow-up supports compliance.

<sup>‡</sup>Prospective studies targeting these high protein intakes in older hemodialysis/peritoneal dialysis patients are not available.




# Data from previous space flight missions



Body mass losses of 1-5% of preflight body mass have been a typical finding in the history of spaceflight



Changes in body weight on the day of landing relative to before flight



US and Russian space programs

the Space Shuttle (N=25), Skylab (N=9), Mir (N=19), ISS Expeditions 1-18 (N=26), Expeditions 19-36 (N=31).

# MISURAZIONI DI POPOLAZIONE



- Capodistria ✓
- Lubiana ✓
- Kranj ✓
- Udine ✓
- Trieste ✓
- Ferrara ✓




## CRITERI PER L' ADESIONE

- ETÀ (non inferiore a 60 anni)
- CAPACITÀ DI CAMMINO PER 2 KM



# SOGGETTI SELEZIONATI

-  Femmine (range età: 60-78 anni)
-  Maschi (range età: 60-77 anni)



# STUDIO DI POPOLAZIONE

## COMPLEX

Questionnaire  
Urine  
Blood  
Anthropometrics, bioimpedance  
Ultrasound visceral fat measurement  
ECG  
Cardiovascular capabilities  
Flexibility  
Maximum force and balance  
Gait  
Reaction time, attention, memory, logic capabilities


circa 3h

## BASIC

Short questionnaire  
Anthropometrics, bioimpedance  
Immediate analysis of capillary blood  
2 km walking test  
dinamometriccs  
10 m walking (3 repetitions)  
flexibility – bent on a bench

circa 1,5h

# ABITUDINI ALIMENTARI



# 24 HOUR RECALL (x2) e QUESTIONARI DI FREQUENZA DI CONSUMO

DATA DI NASCITA \_\_\_\_\_  
 GENERE - UOMO  DONNA

PASTI	ORA	LUOGO	CIBI E BEVANDE: TIPO, QUANTITÀ, CONDIMENTI
Colazione			
Merenda mattina e spuntini			
Pranzo			
Merenda pomeriggio e spuntini			
Cena			
Dopocena			

## ATLANTE FOTOGRAFICO DELLE PORZIONI E DEI PESI

		
Latte 200 ml	CorNFLakes 30 g	Zucchero Cucchiaino = 5 grammi Cucchiaino da tè = 10 grammi Bustina = 5 grammi
		
Pane 60 g	100 g	Olio: cucchiaino da minestra

## QUESTIONARIO ALIMENTARE DI FREQUENZA DEI CONSUMI

DATA \_\_\_\_\_

NOME E COGNOME.....CODICE.....

Il questionario valuta quanto spesso i cibi elencati sono stati assunti nel corso dell'ultimo anno (per frutta e verdura fare riferimento alla stagione, ad es: Quando è stagione di ciliegie, quanto spesso le consuma?)

GRUPPO LATTE E LATTICINI	Più volte al giorno	1x giorno	5-6x settimana	2-4x settimana	1x settimana	1-3x mese	MAI
A - Latte (al naturale, con caffè, orzo, al cioccolato, al cacao, ecc.)	1	2	3	4	5	6	7
B - Yogurt, latte acido, kefir	1	2	3	4	5	6	7
C - Formaggio, ricotta, formaggini	1	2	3	4	5	6	7
D - Panna, panna acida	1	2	3	4	5	6	7
E - Budini al latte, gelato al latte	1	2	3	4	5	6	7
F - Fric	1	2	3	4	5	6	7
G - Grana, parmigiano o stravecchio sui primi piatti	1	2	3	4	5	6	7

CONDIMENTI E GRASSI	Più volte al giorno	1x giorno	5-6x settimana	2-4x settimana	1x settimana	1-3x mese	MAI
A - Burro	1	2	3	4	5	6	7
B - Margarina	1	2	3	4	5	6	7
C - Lardo, ciccioli	1	2	3	4	5	6	7
D - Maionese	1	2	3	4	5	6	7
E - Olio di semi	1	2	3	4	5	6	7
F - Olio di oliva	1	2	3	4	5	6	7

FRUTTA	Più volte al giorno	1x giorno	5-6x settimana	2-4x settimana	1x settimana	1-3x mese	MAI
A - Mele, pere	1	2	3	4	5	6	7
B - Pesche, albicocche, prugne	1	2	3	4	5	6	7
C - Uva	1	2	3	4	5	6	7
D - Banane	1	2	3	4	5	6	7
E - Arance, mandarini	1	2	3	4	5	6	7
F - Fragole, mirtilli, ciliegie (in stagione)	1	2	3	4	5	6	7
G - Anguria, melone (in stagione)	1	2	3	4	5	6	7
H - Kiwi	1	2	3	4	5	6	7
I - Frutta secca zuccherina, tipo prugne, albicocche, ecc.	1	2	3	4	5	6	7
J - Frutta cotta o composta	1	2	3	4	5	6	7
K - Frutta secca oleosa	1	2	3	4	5	6	7
L - Cachi	1	2	3	4	5	6	7

VERDURE	Più volte al giorno	1x giorno	5-6x settimana	2-4x settimana	1x settimana	1-3x mese	MAI
A - Fagioli	1	2	3	4	5	6	7
B - Fagiolini	1	2	3	4	5	6	7
C - Piselli	1	2	3	4	5	6	7
D - Cavolfiori, broccoli	1	2	3	4	5	6	7
E - Carote, cavolo rapa	1	2	3	4	5	6	7
F - Spinaci, biette	1	2	3	4	5	6	7
G - Mais	1	2	3	4	5	6	7
H - Patate	1	2	3	4	5	6	7
I - Pomodori, peperoni	1	2	3	4	5	6	7
J - Crauti, brovada (rape)	1	2	3	4	5	6	7
K - Cavolo capuccio, verza	1	2	3	4	5	6	7
L - Zucchine, cetrioli, melanzane	1	2	3	4	5	6	7
M - Insalata, radicchio (tutti i tipi)	1	2	3	4	5	6	7
N - Barbabietola rossa	1	2	3	4	5	6	7

# CALORIE TOTALI e NUTRIENTI (%)



PROTEINE

CARBOIDRATI

GRASSI

EFSA European Food Safety Authority (2010)


IOM

CARBOIDRATI 45-65% ( $\geq 130$  g/giorno)


PROTEINE 10-35%

GRASSI 20-35%

## UOMINI



## DONNE



# Recommended Dietary Allowance (RDA) for protein

~0.83 g/kg/d

European Food Safety Agency, 2012  
Food and Nutrition Board, 2002

**RDA** —————> No differences between gender and age  
(Conley TB et al. J Nutr Biochem. 2013)

## Optimal protein intake in the elderly

Robert R. Wolfe <sup>a,\*</sup>, Sharon L. Miller <sup>b</sup>, Kevin B. Miller <sup>c</sup>

There is an evidence that **the RDA for elderly** may be **greater than 0.8 g/kg/day** to **improve muscle mass, strength and function** as well as to improve immune status, wound healing, blood pressure and bone health

Clinical Nutrition (2008) 27, 675–684

# Evidence-Based Recommendations for Optimal Dietary Protein Intake in Older People: A Position Paper From the PROT-AGE Study Group

Jürgen Bauer MD<sup>a,\*</sup>, Gianni Biolo MD, PhD<sup>b</sup>, Tommy Cederholm MD, PhD<sup>c</sup>, Matteo Cesari MD, PhD<sup>d</sup>, Alfonso J. Cruz-Jentoft MD<sup>e</sup>, John E. Morley MB, BCh<sup>f</sup>, Stuart Phillips PhD<sup>g</sup>, Cornel Sieber MD, PhD<sup>h</sup>, Peter Stehle MD, PhD<sup>i</sup>, Daniel Teta MD, PhD<sup>j</sup>, Renuka Visvanathan MBBS, PhD<sup>k</sup>, Elena Volpi MD, PhD<sup>l</sup>, Yves Boirie MD, PhD<sup>m</sup>

<sup>a</sup> Geriatric Centre Oldenburg, Oldenburg, Germany

<sup>b</sup> University of Trieste, Trieste, Italy

<sup>c</sup> Uppsala University, Uppsala, Sweden

<sup>d</sup> Université de Toulouse III Paul Sabatier, INSERM UMR1027, Toulouse, France

<sup>e</sup> Hospital Universitario Ramón y Cajal, Madrid, Spain

<sup>f</sup> Saint Louis University School of Medicine, St. Louis, MO

<sup>g</sup> McMaster University, Hamilton, Ontario, Canada

<sup>h</sup> Friedrich-Alexander-University Erlangen-Nürnberg, Nürnberg, Germany

<sup>i</sup> University of Bonn, Bonn, Germany

<sup>j</sup> Centre Hospitalier Universitaire Vaudois, Service de Néphrologie, Lausanne, Switzerland

<sup>k</sup> University of Adelaide, Adelaide, Australia

<sup>l</sup> University of Texas Medical Branch, Galveston, TX

<sup>m</sup> Université d' Auvergne, INRA, CRNH, Centre Hospitalier Universitaire, Clermont-Ferrand, France

HEALTHY  
AGEING

## PROT-AGE recommendations for dietary protein intake in *healthy* older adults

- To maintain and regain muscle, older people need more dietary protein than do younger people: older people should consume an average daily intake in the range of 1.0 to 1.2 g/kg BW/d.
- The per-meal anabolic threshold of dietary protein/amino acid intake is higher in older individuals (ie, 25 to 30 g protein per meal, containing about 2.5 to 2.8 g leucine) in comparison with young adults.
- Protein source, timing of intake, and amino acid supplementation may be considered when making recommendations for dietary protein intake by older adults.
- More research studies with better methodologies are desired to fine tune protein needs in older adults.

# PROTEINE (g/kg PESO IDEALE)



## RACCOMANDAZIONI

EFSA 0.83 g/kg  
 LARN 0.9 g/kg  
**PROT-AGE 1-1.2 g/kg**

**Anziani attivi: 1.2 g /kg minimo**

## MEDIA g/kg

**Uomini 1.13 ± 0.32**

**Donne 1.18 ± 0.34**

Proteine g/kg	UOMINI (%)	DONNE (%)
< 0.8 g/kg <sub>PI</sub> insufficiente	6	11
0.8 – 1.0 g/kg <sub>PI</sub> EFSA - LARN	32	18
1.0 – 1.2 g/kg <sub>PI</sub> PROT-AGE	28	33
>1.2 – g/kg <sub>PI</sub> soggetti attivi	34	34
<b>FONTI ANIMALI/VEGETALI (%)</b>	<b>60 / 40</b>	<b>60 / 40</b>

# SORGENTI DI PROTEINE ANIMALI

**Carne, salumi, pesce, latte e derivati (latticini) uova/100 g peso netto e a crudo**



**Carne o pesce 100 g = 15-20 g**

**Uova per 50 g = 6,2g**

Un uovo pesa mediamente 55g  
guscio 5 g, albume 35 g, tuorlo 15g



**Formaggio grana padano 100 g = 39 g**

**Latte, vaccino intero 100 ml = 3,4 g**

**Da: Tabelle composizione alimenti.**

**CREA Centro di ricerca Alimenti e Nutrizione, aggiornamento 2019**

# SORGENTI DI PROTEINE ANIMALI

Cereali, legumi, noci/100 g peso netto



**100 g = 8 g**



**100 g a crudo = 11-13**



**Fagioli borlotti freschi  
100 g dopo cottura =  
5,7 g Secchi dopo  
cottura**



**100 g = 15 g  
30 g (circa 7 noci) a netto = 4,5 g**

Da: Tabelle composizione alimenti.

CREA. Centro di ricerca Alimenti e Nutrizione, aggiornamento 2019

## CONTENUTO PROTEICO DI ALCUNI TRA I PIÙ COMUNI ALIMENTI ANIMALI E VEGETALI (g/100 g DI PARTE EDIBILE)

Caciocavallo	circa 38	Biscotti di soia	11,5
Soia secca	37	Fette biscottate	11
Parmigiano	33,5	Pasta di semola	11
Bresaola	32	Polpo	11
Arachidi tostate	29	Noci fresche	10,5
Pecorino siciliano	29	Pappa reale	10
Caciotta di pecora	circa 28	Pane	9
Provolone	28	Biscotti secchi	8
Fave secche	27	Pane integrale	7,5
Prosciutto crudo	27	Riso integrale	7,5
Scamorza	25	Cioccolato al latte	7
Fontina	24,5	Cornflakes	7
Fesa di tacchino	circa 24	Riso brillato	7
Fagioli secchi	23	Panettone	6
Petto di pollo	circa 23	Asparagi di bosco	5
Mandorle secche	22	Funghi porcini	4
Lombata/costata di vitellone	circa 21,5	Mais	4
Tonno fresco	21,5	Cocco fresco	3,5
Agnello	21	Fichi secchi	3,5
Bistecca di maiale	21	Latte/yogurt parzialmente scremato	3,5
Ceci secchi	21	Asparagi coltivati	3
Filetti di orata	21	Broccoletti	3
Pagello	21	Castagne fresche	3
Vitello	21	Cavolfiore	3
Sarda	21	Spinaci freschi	3
Fior di latte	17	Patate	2
Spigola	17	Banane	1
Noci secche	14	Bieta	1
Bovino in gelatina	circa 13	Fichi freschi	1
Pasta all'uovo secca	13	Peperoni	1
Piselli freschi	13	Pomodori in insalata	1
Savoardi	12	Zucchine	1
Tortellini freschi	12	Miele	0,6
Uovo intero	12	Mela	0,3

Da: INN, 2000.

# PROTEINE COMPLETE



- ❖ Le proteine complete contengono **quantità, qualità e proporzionalità di amminoacidi essenziali adeguati** a garantire le **sintesi proteiche ottimali** nell'organismo.
- ❖ Sono **complete** le proteine di origine **animale**, a parte le proteine del collagene
- ❖ Sono definite pertanto ad **alto valore biologico** (vedasi infra)

# PROTEINE INCOMPLETE



- ❖ Le proteine **incomplete** contengono **quantità insufficienti di alcuni aminoacidi essenziali** ovvero gli aminoacidi non sono presenti nelle giuste proporzioni a garantire **sintesi proteiche ottimali** nell'organismo
- ❖ Definite pertanto proteine a **medio-basso valore biologico** (vedasi infra)
- ❖ **AMMINOACIDO LIMITANTE** aminoacido a **più bassa concentrazione presente in una proteina** rispetto all'equilibrio o la proporzione di aminoacidi presa come riferimento, ad es, proteine dell'uovo intero. **Sono incomplete le singole proteine di origine vegetale**

# AMMINOACIDI LIMITANTI

in alcuni prodotti vegetali



## CEREALI

Lisina, Treonina , Isoleucina



## LEGUMI

Metionina e Triptofano



**NOCI:** Leucina, Isoleucina

# FREQUENZA DI CONSUMO DI ALIMENTI PROTEICI



	<u>2-4 sett.</u>	<u>MAI</u>
M:	31 %	14 %
F:	24 %	10 %



M:	38 %	6 %
F:	24 %	7 %



M:	40 %	5 %
F:	45 %	5 %



M:	17 %	26 %
F:	9 %	29 %



	<u>2-4 sett.</u>	<u>MAI</u>
M:	45 %	0 %
F:	49 %	0 %




M:	40 %	6 %
F:	44 %	3 %




M:	22 %	11 %
F:	20 %	11 %

# 24 HOUR RECALL e QUESTIONARI DI FREQUENZA DI CONSUMO (x2)

ATLANTE FOTOGRAFICO DELLE PORZIONI E DEI PESI		
		
<b>Latte 200 ml</b>	<b>Corn flakes 30 g</b>	<b>Zucchero</b> Cucchiaino = 5 grammi Cucchiaino da tè = 10 grammi Bustina = 5 grammi
		
<b>Pane 60 g</b>	<b>100 g</b>	<b>Olio: cucchiaino da minestra</b>
		

# PROTEINE (g/kg PESO IDEALE)



RACCOMANDAZIONI	
EFSA	0.83 g/kg
LARN	0.9 g/kg
<b>PROT-AGE</b>	<b>1-1.2 g/kg</b>

Anziani attivi: **1.2 g /kg minimo**

## MEDIA g/kg


**Uomini 1.13 ± 0.32**

**Donne 1.18 ± 0.34**



Proteine g/kg	Uomini %	Donne %
< 1	38	30
1-1.2	28	33
> 1.2	34	37

# LE PROTEINE AI PASTI



**PROT-AGE: 25-30 g proteine ai tre principali pasti della giornata**




**COLAZIONE**



**PRANZO**



**CENA**



	Uomini	Donne
Media proteine nei 3 pasti (g)	25.6	22.0
soggetti < 25 g/pasto (%)	40	77

**>70 years do not assume the current RDA of proteins  
(0.8 g/kg/day).**



The phenomenon depends upon several factors:

- **ODONTOSTOMATOLOGICAL PROBLEMS** → alteration of the masticatory function  
→ influence in the choice of foods;
- **DELAYED GASTRIC EMPTYING**, associated with a reduced gallbladder contractility and higher serum levels of the hormone cholecystokinin (CCK) and neuropeptide Y (PYY) (facilitating a *long-lasting satiety*);
- **HIGHER BLOOD CONCENTRATION OF LEPTIN** in the elderly (showing that the anorexigenic signal prevails over the orexigenic one);

# *protein quality*

- **amino acid composition**
- **absorption kinetics**

# Concentration of major milk proteins


Protein	Concentration (g/l)	
	Cow	Human
<u>Total caseins</u>	<u>26.0</u>	<u>2.7</u>
$\alpha$ -Casein	13.0	
$\beta$ -Casein	9.3	
$\kappa$ -Casein	3.3	
<u>Total whey protein</u>	<u>6.3</u>	<u>67.3</u>
$\beta$ -Lactoglobulin	3.2	
$\alpha$ -Lactalbumin	1.2	1.9
Immunoglobulins (A, M, and G)	0.7	1.3
Serum albumin	0.4	0.4
Lactoferrin	0.1	1.5
Lactoperoxidase	0.03	
Lysozyme	0.0004	0.1
Miscellaneous	0.8	1.1
Proteose-peptone	1.2	
Glycomacropeptide	1.2	

# Amino acid composition of whey and casein



WHEY PROTEIN INGESTION ENHANCES POSTPRANDIAL ANABOLISM DURING SHORT-TERM BED REST IN YOUNG MEN


*Antonione et al., J Nutr 2008*



**Intake of the rapidly absorbed whey protein within a mixed meal optimizes postprandial stimulation of protein synthesis during bed rest.**

**Effects of whey and casein meals on whole body phenylalanine utilization for protein synthesis during bed rest**

# CASEIN AND WHEY ABSORPTION KINETICS



Test Meal

0.4 g/kg whey or casein  
0.27 g/kg sucrose

*J Nutr 2008*

# VALUTAZIONE DELL'EFFICACIA DELLE PROTEINE ALIMENTARI NELLE SINTESI PROTEICHE

## QUALITA' PROTEICA

**Vengono utilizzati diversi metodi:**

1. Misurazione dell'**aumento di peso di animali** che sono **in crescita** (metodo indaginoso)
2. Misurazioni che valutano il **contenuto corporeo di azoto** estrapolato dall'assorbimento e/o dalla digestione della proteina valutata (metodo indaginoso)
3. Misurazioni che fanno riferimento alla **composizione quali-quantitativa degli amminoacidi presenti nella proteina valutata**. Sono più semplici e oggi più utilizzate. Adottate anche dalla FAO, WHO

# VALUTAZIONE DELLA QUALITA' DELLE PROTEINE CON MISURAZIONE DELLA CRESCITA IN ANIMALI

## PROTEIN EFFICIENCY RATIO

$$\text{PER} = \frac{\text{Gain in Body Mass (g)}}{\text{Protein Intake (g)}}$$

**Aumento di peso di un animale in crescita in relazione all'apporto proteico.**  
Confronto con proteina di riferimento ad es. ovoalbumina somministrata a gruppo animali di controllo

**Valori > 2,5-2,7 indicativi di una buona efficacia**

- ❖ Uova 3,8; carne di manzo 2,9;
- ❖ Proteine siero di latte 3,2; Caseina 2,5
- ❖ Proteine soia 2,2

# PROTEINE

## contenuto in azoto

**In media le proteine contengono il 16% di azoto**

**100 g di proteine / 16 g = 6,25 g**


Quantità di proteine in grammi partendo dai grammi di azoto (conversione quantità di azoto in proteine)

**= azoto x 6,25**

Quantità di azoto partendo dai grammi di proteine (conversione quantità di proteine in quantità di azoto)

**= proteine : 6,25**

# VALUTAZIONE DELLA QUALITA' DELLE PROTEINE CON MISURAZIONE DEL CONTENUTO CORPOREO DI AZOTO




## PARAMETRI UTILIZZATI

- ❖ **(I)** = Introito di azoto U(N)
- ❖ **Azoto digerito (D)** = Introito – perdite fecali – perdite fecali a dieta aproteica/introito (sull'ingerito)
- ❖ **Azoto assorbito** = Introito – perdite fecali – perdite fecali a dieta aproteica
- ❖ **Azoto ritenuto** = I – perdite fecali – perdite fecali a dieta aproteica - perdite Urinarie –perdite urinarie a dieta aproteica

# FABBISOGNO PROTEICO MINIMO


## Metodologia



E' stato **definito** tramite valutazione delle **perdite azotate obbligate** in soggetti giovani a dieta priva di proteine per una settimana in associazione ad un apporto di calorie da carboidrati e grassi sufficiente a mantenere il bilancio di energia, senza attivazione di neoglucogenesi

# FABBISOGNO PROTEICO MINIMO

## RISULTATI



❖ **Totale 56 mg/kg di azoto/giorno**

❖ In un soggetto di 70 kg (peso ideale) =  $56 \times 70 = 3,9$  g di azoto.

❖  $3,9 \times 6,25 = \mathbf{24,4}$  g di **proteine**, ovvero 0,35 g di proteine/kg peso ideale

# VALUTAZIONE DELLA QUALITA' DELLE PROTEINE

**VALORE BIOLOGICO (VB):** proporzione dell'azoto (della proteina) assorbito che viene ritenuto e utilizzato per la crescita e il mantenimento corporeo al netto di perdite urinarie e fecali.

- Dipende dalla **composizione in amminoacidi** e dalla presenza di **aminoacidi limitanti**.
- **Non tiene** conto della **digeribilità delle proteine**.

$$BV = \frac{N_{\text{lim}} - N_{\text{feci}} - N_{\text{urine}}}{N_{\text{lim}} - N_{\text{feci}}} \quad \text{N ritenuto / N assorbito}$$

$$BV = \frac{I - (F - F_k) - (U - U_k)}{I - (F - F_k)} \quad \times 100 \quad (\% \text{ dell'azoto utilizzato})$$

**N**= azoto, **I** = Introito di azoto; **F** = perdite fecali di azoto dopo ingestione della proteina testata, **F<sub>k</sub>** perdite fecali di azoto a dieta non proteica

**U** = perdite urinarie di azoto dopo ingestione della proteina testata, **U<sub>k</sub>** perdite urinarie di azoto a dieta non proteica

# DIGERIBILITA' delle PROTEINE

Rapporto tra proteina introdotta meno perdite fecali e quota di proteina ingerita

$$\text{Digeribilità, } D = \frac{I - (F - F_k)}{I} \times 100$$

Rapporto tra assorbito e introdotto

I = Introito di azoto;

F perdite fecali di azoto dopo ingestione della proteina testata

F<sub>k</sub> perdite fecali di azoto a dieta non proteica

# VALUTAZIONE DELLA QUALITA' DELLE PROTEINE

## UTILIZZAZIONE PROTEICA NETTA (NET PROTEIN UTILIZATION, NPU)

Si ottiene moltiplicando il **valore biologico** (N ritenuto su N assorbito) per la **digeribilità** (assorbito su introdotto della proteina testata)

$$VB \times D = \frac{I - (F - F_k) - (U - U_k)}{I - (F - F_k)} \times \frac{I - (F - F_k)}{I} =$$


$$NPU = \frac{I - (F - F_k) - (U - U_k)}{I} \quad \text{Valuta N ritenuto su N introdotto}$$

**N** = azoto **VB** = valore biologico , = Introito di azoto; **F** perdite fecali di azoto dopo ingestione della proteina testata,

**F<sub>k</sub>** perdite fecali di azoto a dieta non proteica; **U**= perdite urinarie dopo ingestione proteina testata e **U<sub>k</sub>** perdite urinarie di azoto a dieta non proteica

# FABBISOGNO PROTEICO CON PROTEINE A DIVERSO NPU, NET PROTEIN UTILIZATION (BV x digeribilità)

NPU	Fabbisogno proteico g/kg
94 % uova	0,66
80% pesce	0,74
67 % vitello	0,84
61% soia	0,98
40% frumento	1,20



**Gli studi con Bilancio dell'azoto** =  $\text{proteine introdotte, g azoto die} / 6,25) - [\text{UUN azoto ureico urinario g/die} + \text{UNUN, Urinary Non Urea Nitrogen, (dato da acido urico e creatinina escreti nelle urine)} + 2-4 \text{ g equiparati alla somma di perdite di azoto fecali} + \text{altre perdite})$  **hanno rilevato che la neutralità del bilancio richiede quote di apporto proteico diverse, in relazione al NPU della proteina testata**

**Per ottenere bilancio azoto neutro servono più proteine derivate da prodotti vegetali rispetto a prodotti di origine animale**

# VALUTAZIONE DELLA QUALITA' DELLE PROTEINE TRAMITE DOSAGGIO AMMINOACIDICO

DIGERIBILITÀ DELLE PROTEINE CORRETTA PER L'AMMINOACIDO LIMITANTE  
Protein Digestibility-Corrected Amino Acid Score (PDCAAS)

$$\frac{I - (F - F_k)}{I} \times \frac{\text{AA limitante mg/g proteina testata}}{\text{Stesso AA mg/g proteina di riferimento}}$$

**Digeribilità proteina testata**

- ❖ **PDCAAS** è basato sul fabbisogno di aminoacidi nell'uomo, sia sulla capacità di digerire le proteine ingerite
- ❖ Secondo la FAO e WHO, **uno score = 1** indica che **la proteina soddisfa il fabbisogno di tutti gli aminoacidi essenziali**
- ❖ Tuttavia il **PDCAAS non considera il surplus di aminoacidi essenziali presenti in alcune proteine** che possono compensare i più bassi livelli presenti in altre

# VALUTAZIONE DELLA QUALITA' DELLE PROTEINE CON DIVERSE METODOLOGIE

**Table 1.** Protein quality rankings.

<b>Protein Type</b>	<b>Protein Efficiency Ratio</b>	<b>Biological Value</b>	<b>Net Protein Utilization</b>	<b>Protein Digestibility Corrected Amino Acid Score</b>
<b>Beef</b>	2.9	80	73	0.92
<b>Black Beans</b>	0		0	0.75
<b>Casein</b>	2.5	77	76	1.00
<b>Egg</b>	3.9	100	94	1.00
<b>Milk</b>	2.5	91	82	1.00
<b>Peanuts</b>	1.8			0.52
<b>Soy protein</b>	2.2	74	61	1.00
<b>Wheat gluten</b>	0.8	64	67	0.25
<b>Whey protein</b>	3.2	104	92	1.00

Adapted from: U.S Dairy Export Council, Reference Manual for U.S. Whey Products 2nd Edition, 1999 and Sarwar, 1997.

**Hoffman JR. Journal of Sports Science and Medicine (2004) 3, 118-130**

# PDCAAS


## Score di diversi cibi

1	Latte di mucca
1	Uova
1	Caseina
1	Proteine della soia
1	Pupe di bachi da seta
1	Whey (proteine siero di latte)
0.92	Carne di manzo
0.893	Proteine di piselli concentrate
0.78	Ceci
0.75	Fagioli neri

0.70	Legumi media
0.687	Grilli
0.64	Frutta fresca
0.59	Cereali e derivati
0.52	Arachidi
0.50	Riso
0.48	Frutta secca oleosa, noci
0.525	Crusca di frumento
0.42	Frumento
0.25	Glutine di frumento

# PROTEINE COMPLEMENTARI

Proteine alimentari la cui **associazione** in un pasto **rende l'apporto proteico completo** per compensazione delle reciproche carenze parziali di aminoacidi (riportate all'interno dei cerchi)



# PDCAAS E COMPLEMENTARIETA' DEGLI ALIMENTI

**Combinando** diversi cibi è possibile **massimizzare lo score del PDCAAS** in quanto i **diversi componenti completano** a vicenda le quote di aminoacidi essenziali. La complementarietà può essere ottenuta **abbinando proteine vegetali con proteine animali oppure con l'associazione di proteine vegetali di diversa tipologia**

**Piselli cotti 0,597 + Riso 0,50**




<b>1,097</b>	Riso e piselli
<b>1</b>	Cereali, noci e semi
<b>1</b>	Legumi, noci e semi
<b>0,92</b>	Riso e latte

**PDAAS. Protein digestibility corrected AA score**


# *Amino Acids*

# BRANCHED CHAIN AMINO ACIDS (BCAA)


- Essential amino acids




- BCAAs in humans elevates the phosphorylation and the activation of p70S6 kinase and 4E-BP1 in skeletal muscle




## BRANCHED CHAIN AMINO ACIDS (BCAA)



- BCAAs in humans elevates the phosphorylation and the activation of p70S6 kinase and 4E-BP1, downstream components of the mTOR signaling pathway, which controls RNA translation and synthesis of proteins, and which is recognized as the central node to support muscle hypertrophy



# Leucine enhances the insulin stimulatory effect on mTOR under conditions of hormonal resistance



*The FASEB Journal* express article 10.1096/fj.03-1409fje. Published online October 12, 2004.

**Amino acids and leucine allow insulin activation of the PKB/mTOR pathway in normal adipocytes treated with wortmannin and in adipocytes from *db/db* mice**

Charlotte Hinault,\* Isabelle Mothe-Satney,\* Nadine Gautier,\* John C. Lawrence, Jr.,<sup>†</sup> and Emmanuel Van Obberghen\*

*Layman & Walker 2006*

## A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly

Christos S. Katsanos,<sup>1</sup> Hisamine Kobayashi,<sup>2</sup> Melinda Sheffield-Moore,<sup>3</sup>  
Asle Aarsland,<sup>4</sup> and Robert R. Wolfe<sup>1</sup>

Departments of <sup>1</sup>Surgery and Shriners Hospitals for Children-Galveston, <sup>3</sup>Internal  
Medicine, and <sup>4</sup>Anesthesiology, University of Texas Medical Branch, Galveston, Texas;  
and <sup>2</sup>AminoScience Laboratories, Ajinomoto Company, Incorporated, Kawasaki, Japan




Fig. 5. Fractional synthetic rate (%/h) of mixed muscle protein in the basal state (Basal) and after the ingestion of 6.7 g of EAA (Post-EAA) containing either 1.7 (26% Leu) or 2.8 (41% Leu) g of leucine. \*Significantly different from the corresponding basal value ( $P < 0.05$ ).

# Leucine co-ingestion improves post-prandial muscle protein accretion in elderly men


Benjamin T. Wall, Henrike M. Hamer, Anneke de Lange, Alexandra Kiskini, Bart B.L. Groen, Joan M.G. Senden, Annemie P. Gijsen, Lex B. Verdijk, Luc J.C. van Loon\*

Department of Human Movement Sciences, NUTRIM School for Nutrition, Toxicology and Metabolism, Maastricht University Medical Centre, PO Box 616, Maastricht, 6200 MD, The Netherlands



Clinical Nutrition 32 (2013) 412–419

**Methods:** Twenty-four elderly men ( $74.3 \pm 1.0$  y) were randomly assigned to ingest 20 g intrinsically  $\text{L}$ -[1- $^{13}\text{C}$ ]phenylalanine-labeled casein protein with (PRO + LEU) or without (PRO) 2.5 g crystalline leucine.



Mean ( $\pm$ SEM) delta protein-bound  $\text{L}$ -[1- $^{13}\text{C}$ ]phenylalanine enrichments (MPE) during a 2 and 6 h incorporation period following the ingestion of 20 g intrinsically  $\text{L}$ -[1- $^{13}\text{C}$ ]phenylalanine-labeled casein with (PRO + LEU;  $n = 12$ ) or without (PRO;  $n = 12$ ) 2.5 g crystalline leucine in healthy, elderly men. Data were analyzed with an unpaired, two-tailed Student's  $t$ -test. \* $P < 0.05$  compared with corresponding time point in the PRO group.

# Long-term leucine supplementation does not increase muscle mass or strength in healthy elderly men<sup>1-3</sup>

Suzanne Verhoeven, Kristof Vanschoonbeek, Lex B Verdijk, René Koopman, Will KWH Wodzig, Paul Dendale, and Luc JC van Loon

*Am J Clin Nutr* 2009;89:1468–75.

Leucine or placebo (2.5 g) was administered with each main meal during a 3-mo intervention period.

## Body composition<sup>1</sup>

	Placebo (n = 14)		Leucine (n = 15)	
	Before	After	Before	After
Lean mass (kg)	55.8 ± 0.9	56.2 ± 1.1	54.6 ± 1.0	55.0 ± 1.5
Fat mass (kg)	19.8 ± 1.7	19.2 ± 2.0	20.0 ± 1.4	20.0 ± 1.3
Body fat (%)	24.5 ± 1.7	23.9 ± 1.9	25.3 ± 1.2	25.4 ± 1.2
Leg lean mass (kg)	17.6 ± 0.4	18.0 ± 0.4	17.1 ± 0.5	17.6 ± 0.4
Leg fat (%)	18.9 ± 1.5	19.4 ± 1.6	19.6 ± 1.2	19.8 ± 1.2
CSA (cm <sup>2</sup> )	71 ± 3	71 ± 3	71 ± 2	71 ± 2
Leg volume (L)	7.5 ± 1.9	7.5 ± 1.7	8.1 ± 3.0	7.8 ± 4.1

**Results:** No changes in skeletal muscle mass or strength were observed over time in either the leucine- or placebo-supplemented group. No improvements in indexes of whole-body insulin sensitivity (oral glucose insulin sensitivity index and the homeostasis model assessment of insulin resistance), blood glycated hemoglobin content, or the plasma lipid profile were observed.

<sup>1</sup> All values are means ± SEMs. CSA, cross-sectional area. Data were analyzed by using repeated-measures ANOVA. No significant differences were observed between groups or over time.

## Glycemic control<sup>1</sup>



	Placebo (n = 14)					Leucine (n = 15)				
	0	2	4	8	12	0	2	4	8	12
Plasma glucose (mmol/L)	5.54 ± 0.11	5.63 ± 0.13	5.62 ± 0.12	5.75 ± 0.13	5.49 ± 0.10	5.69 ± 0.18	5.77 ± 0.18	5.86 ± 0.15	5.85 ± 0.17	5.66 ± 0.16
Plasma insulin (mU/L)	6.04 ± 0.76	6.08 ± 0.82	4.66 ± 0.54	6.37 ± 1.04	6.15 ± 1.25	6.73 ± 0.68	8.22 ± 0.91	9.03 ± 1.45	8.34 ± 1.44	7.37 ± 1.17
Hb A <sub>1c</sub> (%)	5.8 ± 0.1	5.6 ± 0.1	5.6 ± 0.1	5.6 ± 0.1	5.8 ± 0.1	5.9 ± 0.1	5.8 ± 0.1	5.8 ± 0.1	5.8 ± 0.1	5.9 ± 0.1
HOMA-IR	1.51 ± 0.21	1.55 ± 0.23	1.19 ± 0.16	1.66 ± 0.29	1.54 ± 0.33	1.74 ± 0.21	2.12 ± 0.26	2.38 ± 0.4	2.19 ± 0.39	1.89 ± 0.32
Glucose <sub>120 min</sub> OGTT	7.16 ± 0.67	—	—	—	5.44 ± 0.49	6.76 ± 0.5	—	—	—	6.76 ± 0.65
OGIS (mL · min <sup>-1</sup> · m <sup>-2</sup> )	876 ± 40	—	—	—	939 ± 40	924 ± 44	—	—	—	906 ± 42

<sup>1</sup> All values are means ± SEMs. HOMA-IR, homeostasis model assessment of insulin resistance; OGIS, oral glucose insulin sensitivity; OGTT, oral-glucose-tolerance test; Hb A<sub>1c</sub>, glycated hemoglobin. Data were analyzed by using repeated-measures ANOVA. No significant differences were observed between groups or over time.

# Effects of leucine and its metabolite

## $\beta$ -hydroxy- $\beta$ -methylbutyrate on human skeletal muscle protein metabolism

*J Physiol* 591.11 (2013) pp 2911–2923



Consumption of small amounts ( $\sim$ 2–3 g) of either Leu or its metabolite HMB resulted in the acute increase of MPS to a degree comparable to that seen after a mixed meal, with HMB also suppressing MPB.

# Effect of $\beta$ -hydroxy- $\beta$ -methylbutyrate (HMB) on lean body mass during 10 days of bed rest in older adults

Nicolaas E.P. Deutz<sup>a,\*</sup>, Suzette L. Pereira<sup>b</sup>, Nicholas P. Hays<sup>a</sup>, Jeffery S. Oliver<sup>b</sup>, Neile K. Edens<sup>b</sup>, Chris M. Evans<sup>a</sup>, Robert R. Wolfe<sup>a</sup>

<sup>a</sup>Center for Translational Research in Aging & Longevity, Donald W. Reynolds Institute on Aging, University of Arkansas for Medical Sciences, Little Rock, AR, USA

<sup>b</sup>Abbott Nutrition, Columbus, OH, USA



Clinical Nutrition 32 (2013) 704–712

**Design:** A randomized, controlled, double-blinded, parallel-group design study was carried out in 24 healthy (SPPB  $\geq 9$ ) older adult subjects (20 women, 4 men), confined to complete bed rest for ten days, followed by resistance training rehabilitation for eight weeks. Subjects in the experimental group were treated with HMB (calcium salt, 1.5 g twice daily – total 3 g/day). Control subjects were treated with an inactive placebo powder. Treatments were provided starting 5 days prior to bed rest till the end rehabilitation phase. DXA was used to measure body composition.




Fig. 1. Change in total lean mass in individual subjects over 10-day bed rest in Control (●) and HMB (■). Line with error bars represent mean  $\pm$  SEM for each group. Values from all subjects (Control  $n = 8$ ; HMB  $n = 11$ ). X indicates potential outlier from HMB group. Difference between treatment groups was non-significant ( $p = 0.16$ , ANOVA). When data are analyzed from all Control subjects ( $n = 8$ ) and HMB subjects excluding potential outlier, thus a total of 10 subjects, the difference between treatment groups is significant ( $p = 0.02$ , ANOVA).

Author	Clinical setting	Subjects	Daily dose	Duration	Changes in body composition/function				Additional effects	Overall efficacy
					BM	FFM	FM	Strength		
Hsieh et al. (2010)	Old age-related wasting	79 bed-ridden elderly receiving tube feeding (43 M, 36 F)	2 g HMB (nasogastric feeding tube)	2 or 4 wk (39 subjects continued the study for another 14 days)	=(2 wk or 4 wk)	NA	NA	NA	Waist circumference: (+) (2, or 4 weeks) Red blood cells: -(2 week) Hemoglobin: -(2 weeks) BUN: -(2 weeks) UUN: -(2 or 4 weeks) Calf circumference: + (4 weeks) Plasma uric acid: -(4 weeks)	Y
Vukovich et al. (2001a, b)	Old age-related wasting	31 old adults (15 M, 16 F)	3 g HMB	8 wk (during training)	=	(+)	-	(+)	Plasma HMB: +	Y
Baier et al. (2009)	Old age-related wasting	77 elderly subjects (38 M, 39 F)	2 g or 3 g HMB (if >68 kg)/5 or 7.5 g ARG (if >68 kg)/1.5 or 2.25 g LYS (if >68 kg)/0.1 g ascorbic acid	1 year	+	+	=	=	BCM: + TBW: + ICW: + ECW: = Functionality: = Protein synthesis: + Protein breakdown: + Protein turnover: + Dietary intake: = Psychological well-being: = Quality of life: = Blood chemistry/hematology: =	Y
Flakoll et al. (2004)	Old age-related wasting	50 elderly subjects (50 F)	2 g HMB/5 g ARG/1.5 g LYS/0.5 g ascorbic acid	12 wk	=	(+)	=	+	"Get-up-and-go" functionality test: + Average limb circumferences: + Abdomen and hip circumferences: (-) UUN: - Proteolysis: = Net protein gain: = Protein synthesis: + Plasma arginine: (+) Dietary intake: = Plasma hormones/amino acids: =	Y
Fuller et al. (2011a, b)	Old age-related wasting	77 elderly subjects (38 M, 39 F)	2 g HMB/5 g ARG/1.5 g LYS (1.5 x dosage if weighing >68 kg)	1 year	NA	+	NA	+		Y
Williams et al. (2002)	Collagen deposition	35 healthy elderly subjects (8 M, 27 F)	3 g HMB/14 g ARG/14 g GLN	2 wk	NA	NA	NA	NA	Plasma arginine: + Plasma ornithine: + Collagen accumulation: + OHP content: + Total protein deposition: = $\alpha$ -AN: =	Y


**Beta-hydroxy-beta-methylbutyrate supplementation in health and disease: a systematic review of randomized trials**

Alessio Molino · Gianfranco Gioia · Filippo Rossi Fanelli · Maurizio Muscaritoli

Amino Acids 2013


DOI 10.1007/s00726-013-1592-z

# Regulation of muscle protein balance in the fasting and postprandial states



*AJPENDO 1995, AJPENDO 1997, Diabetes 1999*



# Regulation of muscle protein balance in the fasting and postprandial states at rest and after exercise



# Exercise Training for Physical Frailty in Very Elderly People


*Fiatarone et al., New Engl J Med 1994*

Randomized, placebo-controlled trial. 100 frail nursing home residents. Progressive resistance exercise training over a 10-week period.




## Age-related differences in the dose–response relationship of muscle protein synthesis to resistance exercise in young and old men

Vinod Kumar<sup>1</sup>, Anna Selby<sup>1</sup>, Debbie Rankin<sup>1</sup>, Rekha Patel<sup>1</sup>, Philip Atherton<sup>1</sup>, Wulf Hildebrandt<sup>1</sup>, John Williams<sup>2</sup>, Kenneth Smith<sup>1</sup>, Olivier Seynnes<sup>3</sup>, Natalie Hiscock<sup>4</sup> and Michael J. Rennie<sup>1</sup>



**Figure 2. Dose–response relationship of myofibrillar protein synthesis (FSR, fractional synthetic rate, % h<sup>-1</sup>) measured at 1–2 h post-exercise for 5 young men and 5 older men at each intensity**

The responses of the young men overall were greater than those of the older men ( $P < 0.04$ ). The responses between 60 and 90% of 1 RM in young and old were indistinguishable from each other but those in the young were together significantly higher than in the older men ( $P < 0.01$ ) for 15 subjects in each group




**Figure 4. Time courses of the responses of phosphorylation of p70s6K and 4EBP1 (arbitrary units as percentage basal for each subject) averaged for intensities of 60–90% 1 RM  $n = 15$  in each group. \* $P < 0.05$ .**

**Older men show anabolic resistance of signalling and myofibrillar protein synthesis to resistance exercise.**



## Age-related anabolic resistance after endurance-type exercise in healthy humans

William J. Durham,<sup>\*,1</sup> Shanon L. Casperson,<sup>\*,1</sup> Edgar L. Dillon,<sup>\*</sup> Michelle A. Keske,<sup>¶</sup> Douglas Paddon-Jones,<sup>\*,†</sup> Arthur P. Sanford,<sup>‡</sup> Robert C. Hickner,<sup>¶</sup> James J. Grady,<sup>§</sup> and Melinda Sheffield-Moore<sup>\*,2</sup>

<sup>\*</sup>Department of Internal Medicine, <sup>†</sup>Department of Physical Therapy, <sup>‡</sup>Department of Surgery, and <sup>§</sup>Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, Texas USA; <sup>¶</sup>Human Performance Laboratory, East Carolina University, Greenville, North Carolina, USA; and <sup>1</sup>Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia



**Aging induces anabolic resistance following endurance exercise, manifested as reduced (by 40%) efficiency of muscle protein synthesis.**



## A transient antioxidant stress response accompanies the onset of disuse atrophy in human skeletal muscle

Luciano Dalla Libera,<sup>1</sup> Barbara Ravara,<sup>2</sup> Valerio Gobbo,<sup>1</sup> Elena Tarricone,<sup>2</sup> Maurizio Vitadello,<sup>1</sup> Gianni Biolo,<sup>3</sup> Giorgio Vescovo,<sup>4</sup> and Luisa Gorza<sup>2</sup>

<sup>1</sup>Consiglio Nazionale delle Ricerche-Institute for Neuroscience, and <sup>2</sup>Department of Biomedical Sciences, University of Padova, Padova; <sup>3</sup>Department of Clinical, Technological and Morphological Sciences, Division of Internal Medicine, University of Trieste, Trieste; and <sup>4</sup>Division of Internal Medicine, San Bortolo Hospital, Vicenza, Italy

*J Physiol* 588.24 (2010) pp 5089–5104

## Effects of inactivity on human muscle glutathione synthesis by a double-tracer and single-biopsy approach

Francesco Agostini<sup>1</sup>, Luciano Dalla Libera<sup>2</sup>, Jörn Rittweger<sup>3</sup>, Sara Mazzucco<sup>1</sup>, Mihaela Jurdana<sup>4</sup>, Igor B. Mekjavic<sup>5</sup>, Rado Pišot<sup>4</sup>, Luisa Gorza<sup>2</sup>, Marco Narici<sup>6</sup> and Gianni Biolo<sup>1</sup>

<sup>1</sup>Department of Medical, Technological and Translational Sciences, Division of Internal Medicine, University of Trieste, Trieste, Italy

<sup>2</sup>CNR-Institute for Neuroscience, Padova Section, and Department of Biomedical Sciences, University of Padova, Padova, Italy



<sup>3</sup>Institute of Aerospace Medicine, Department of Space Physiology, German Aerospace Center, Cologne, Germany

<sup>4</sup>Institute of Kinesiology Research, Science and research centre of Koper, University of Primorska, Koper, Slovenia

<sup>5</sup>Department of Automation, Biocybernetics and Robotics, Jozef Stefan Institute, Ljubljana, Slovenia

<sup>6</sup>Institute for Biomedical Research into Human Movement and Health, Manchester Metropolitan University, Manchester, UK

# Effects of 5-wk bed rest on muscle oxidative stress and anti-oxidant capacity




■ Ambulatory  
■ Bed rest


MUSCLE PROTEIN CARBONYLATION

CHANGES IN GLUTATHIONE SYNTHESIS

CHANGES IN PROTEIN CARBONYLATION



mmol · mg muscle<sup>-1</sup> · day<sup>-1</sup>




GLUTATHIONE SYNTHESIS RATE

# RELATIONSHIPS BETWEEN PATHWAYS OF GLUTATHIONE SYNTHESIS AND DISPOSAL


plasma GSH ~ 5-10  $\mu$ M

cell GSH ~ 1-5 mM




TS, transulfuration; TM, transmethylation; RM, remethylation; GCL, glutamate cysteine ligase; GR, glutathione reductase; GP, glutathione peroxidase; GS, glutathione synthetase;  $\gamma$ GTP,  $\gamma$ -glutamyl transpeptidase.

**Relationship between cysteine concentration and  
glutathione synthesis in erythrocytes  
(L[D<sub>2</sub>]cysteine incorporation in healthy volunteers)**



# Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial

*Lancet* 2005; 365: 1552-60



N-acetylcysteine	256	237	220	206	197	190	186
Hip fractures	267	233	210	197	185	175	168

# Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study

*Lancet* 2008; 371: 2013-18

	Risk ratio	95% CI	p
<b>COPD stage</b>			
Stage IV/stage II	1.44	1.07-1.94	0.015
Stage III/stage II	1.24	1.01-1.53	0.037
<b>Treatment</b>			
Carbocisteine/placebo	0.74	0.61-0.89	0.002

*Table 2: Risk ratio of exacerbation affected by GOLD-defined COPD severity and treatment with carbocisteine*



Original article


## Amino acid supplementation in L-dopa treated Parkinson's disease patients

A. Cucca<sup>a</sup>, S. Mazzucco<sup>b</sup>, A. Bursomanno<sup>c</sup>, L. Antonutti<sup>c</sup>, F.G. Di Girolamo<sup>b</sup>, G. Pizzolato<sup>c</sup>, N. Koscica<sup>c</sup>, G.L. Gigli<sup>a</sup>, M. Catalan<sup>c</sup>, G. Biolo<sup>b,\*</sup>

<sup>a</sup> University of Udine, Clinica Neurologica, Department of Experimental and Clinical Medical Sciences, Italy

<sup>b</sup> University of Trieste, Clinica Medica, Department of Medical, Surgical and Health Sciences, Italy

<sup>c</sup> University of Trieste, Clinica Neurologica, Department of Medical, Surgical and Health Sciences, Italy



**Fig. 2.** Erythrocyte oxidized glutathione (GSSG) concentrations was reported at baseline (T0) and as mean of data collected after 3 and 6 months of treatment (mean T6-T3) with daily amino acid (Intervention group) or placebo (Placebo group) supplementation. There was a statistically significant time effect ( $p = 0.05$ ) over the observation period as well as a statistically significant time  $\times$  treatment interaction ( $p = 0.05$ ), as determining using the repeated measure ANCOVA.

# VALUTAZIONI ANTROPOMETRICHE

- BILANCIA E STADIOMETRO:

✓ Peso

✓ Altezza



Indice di massa corporea (IMC) =  
(Peso, kg) / (Altezza, m)<sup>2</sup>


**Per una corretta valutazione si deve considerare anche l'ETÀ!**

VALORI DI RIFERIMENTO IMC  
(popolazione anziana):

- <21 kg/m<sup>2</sup>: rischio malnutrizione
- 21-23 kg/m<sup>2</sup>: accettabile
- 23-25 kg/m<sup>2</sup>: ottimale
- 25-30 kg/m<sup>2</sup>: sovrappeso



# INDICE DI MASSA CORPOREA



**Stesso indice di massa corporea ma differente proporzione tra massa muscolare e tessuto adiposo**


# Measuring Technique for body composition

## Body mass index (BMI):

- No distinction between Fat Mass and Fat-Free Mass
- No information about fat distribution
- Not very sensible in elderly subjects

## Waist Circumference (WC):

- Highly correlation with BMI



Biolo et al. Clin Nutr 2015

Measuring techniques	Measurements	Comments
Muscle size		
CT Scan	Muscle cross-sectional area	Radiation exposure, expensive
MRI Scan	Muscle cross-sectional area	Expensive, availability of MRI
BIA	Tissue conductivity	? reliability
Muscle circumferences	Mid arm and calf circumference	Measurements effected by subcutaneous fat
DXA scan	Total skeletal muscle mass	Reliable, low radiation exposure

**Abbreviations:** CT, computed tomography; MRI, magnetic resonance imaging; BIA, bioelectric impedance analysis; DXA, dual energy X-ray absorptiometry; SPPB, Short Physical Performance Battery.


# ROLE OF TARGETED INTERVENTIONS TO MAINTAIN OR ENHANCE MUSCLE MASS

- **Exercise training**
  - n-3 FATTY ACIDS
- **High-quality protein intake**
- **Specific Amino Acids**
  - BCAA
  - LEUCINE
  - HMB
  - CYSTEINE
- **Energy balance**

# COMPONENTI DEL FABBISOGNO PROTEICO

- ❖ Quota minima di fabbisogno pari alle perdite obbligate 24,4 g/giorno (risultati studi su fabbisogno proteico minimo bilancio d'azoto )
- ❖ + quota del 30% che tiene conto dell'inefficacia di digestione e assorbimento (x 1,3)
- ❖ + quota del 30% che tiene conto della variabilità individuale presente nella popolazione nel fabbisogno (x 1.3)
- ❖ diversa efficienza di utilizzazione delle proteine presenti in diete con proteine di tipo misto (vegetali e animali) : 0,75

**= 55 G DI PROTEINE TOTALI, 55:70 kg di  
peso = 0,78 g**



**0,8 g-0,9 /kg di peso ideale**

# **INTROITO PROTEICO RACCOMANDATO**

## **PROTEINE (g/kg peso ideale)**

**EFSA**            **0.83 g/kg per adulti senza distinzione sesso ed età**

**LARN**            **0.9 g/kg, dai 18 fino ai 65 anni di età**  
**1-1,2 g/kg oltre 65 anni di età**

**PROT-AGE**    **1-1,2 g/kg per soggetti anziani**

**Anziani attivi: 1,2 g /kg minimo**